Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22508855.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0953.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lee and colleagues report that increase in serum cholesterol is associated with improved clinical outcomes in patients with renal cell carcinoma treated with temsirolimus. Although these findings must be validated prospectively, it should also be determined if this marker is a true mechanism-based toxicity or an epiphenomenon associated with therapy.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Renal Cell
- Cholesterol
- Kidney Neoplasms
- Sirolimus